Different influence of ovine estrus synchronization treatments on caruncular early angiogenesis.
The present study compares two protocols for ovine estrus synchronization by assessing the caruncular angiogenic response to the establishment of pregnancy. The analysis consisted of the immunohistochemical evaluation of Vascular Endothelial Growth Factor (VEGF), Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1, CD31) and Von Willebrand Factor (vWF) in ovine caruncular stroma. A flock of thirty-eight adult ewes was divided in two groups and synchronized with either progestagens (Group P) or prostaglandin analogues (Group PG). Immunohistochemistry was performed in uterine samples obtained from pregnant ewes (P, n=15; PG, n=13) on days 15 post coitus (pc), 17pc and 21pc (day 0 =day of estrus). Each factor was assessed by total vascular density (TVD, total positive blood vessels/mm2), capillary vascular density (CVD, positive blood capillaries/mm2) and arteriolar vascular density (AVD, positive arterioles/mm2). Group P demonstrated higher VEGF-CVD (P=0.045) when compared to prostaglandin treated animals. Vascular CD31-expression decreased on days 15pc and 21pc (TVD, P=0.007 and CVD, P=0.014) in both groups. vWF analysis did not show significant differences between groups or days of study. These results demonstrate a different influence of progestagen-based and prostaglandin analogues-based synchronization treatments over VEGF vascular expression during caruncular development taking place in response to pregnancy establishment. In addition, observations pointed out in this study support the involvement of CD31 in the angiogenic stimulus that occurs during early maternal placentation in the ewe.
Department of Animal Medicine and Surgery, School of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain. ireruiz@vet.ucm.es
I
I
Ruiz-González
M A
MA
Sánchez
R A
RA
García-Fernández
P
P
García-Palencia
B
B
Sánchez
A
A
González-Bulnes
J M
JM
Flores
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D004971:Estrus / Q000187:drug effects*; D004973:Estrus Synchronization / Q000187:drug effects* / Q000502:physiology; D005260:Female; D019290:Megestrol Acetate / Q000494:pharmacology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010920:Placenta / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011247:Pregnancy; D011453:Prostaglandins / Q000494:pharmacology; D012756:Sheep; D014599:Uterus / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D015415:Biomarkers; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011453:Prostaglandins; D042461:Vascular Endothelial Growth Factor A; C049594:cymegesolate; D019290:Megestrol Acetate